Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel, its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial. Long-Term Safety and TolerabilityIn a 54 week open-label safety and tolerability study of 354 patients with advanced Parkinson's disease, the primary endpoint of safety showed adverse events were mostly mild to moderate, were generally associated with the Percutaneous Endoscopic Gastrostomy tube placement procedure and its complications, were transient, and resolved over time.
Some Asian stock markets rose on Wednesday following a positive lead from Wall Street, with Japan's Nikkei reaching …